The Lawn Mower® 4.0 by MANSCAPED™ Now Available Internationally
21.7.2021 16:00:00 EEST | Business Wire | Press release
You ready to rock the landscaped look? Let’s get mowin’. Today, MANSCAPED™ , the global leader and category creator of men’s below-the-waist grooming, announces the international launch of its fourth-generation electric trimmer, The Lawn Mower® 4.0 . Designed and engineered specifically for groin and body grooming, the brand’s newest masterpiece focuses on intelligent functionality, maximum performance and, of course, a superior below-the-waist grooming experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005277/en/
The moment you’ve all been waiting for. Men around the world can now get their hands on MANSCAPED’s fourth-generation groin and body trimmer. (Graphic: Business Wire)
What’s more, The Lawn Mower 4.0 has been integrated into MANSCAPED’s thoughtfully curated bundles for the ultimate self-care routine. The hotly anticipated device and newly elevated kits are now shipping to the United Kingdom, the European Union, Norway, Switzerland, Australia, and New Zealand, in addition to the United States and Canada.
“The global launch of The Lawn Mower 4.0 and our newest packages means getting our latest and most exciting innovations into the hands of millions of men all over the world,” said Paul Tran, Founder and CEO of MANSCAPED. “It’s milestones like these that further advance our vision of driving the movement that changes the face of male grooming — something we’re both humbled by and proud to do every day and with every launch.”
What can you expect with the latest and greatest debuting from the global grooming giant? We’re glad you asked...
The Lawn Mower® 4.0 Groin Trimmer
Proven product attributes and state-of-the-art upgrades come together to make this tool the marquee groin and body trimmer on the market.
Core Features:
- SkinSafe® technology to help reduce the risk of nicks, snags, and tugs
- Powerful 7,000 RPM motor with QuietStroke™ technology
- Rechargeable 600 mAh li-ion battery
- Waterproof design for convenient wet or dry operation
New Enhancements:
- Wireless charging system with electromagnetic induction
- 4000k LED spotlight with diffuser so you can see where you’re trimming
- Cutting-edge ceramic blade to help reduce grooming accidents
- Adjustable trimming guard sizes 1 to 4, with 3, 6, 10, or 13mm settings
- Modern two-toned black finish and powerful packaging presentation
- Travel lock for safety - and racking up frequent flier miles
To up-level your grooming game, or give the greatest gift ever, consider exploring MANSCAPED’s luxury kits that combine The Lawn Mower 4.0 with an array of other top-selling tools, formulations, and accessories. When used together, cleanliness and confidence are abounding.
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver® Ball Deodorant - Avoid stenchy under regions and the dreaded “swamp crotch”; infused with cooling aloe vera, this formulation helps combat sweat and unwanted odor down there
- Crop Reviver® Ball Toner - This spray is the solution for maintaining hygiene and freshness, especially when on-the-go; relieve high-friction areas and post-shave irritation with just a spritz
- This bundle’s free gifts include The Shed premium travel bag and the much acclaimed MANSCAPED™ Boxers made with a microfiber blend
Add another essential men's grooming tool into the mix with this kit featuring MANSCAPED’s premier above-the-waist tool.
- The Weed Whacker® Nose & Ear Hair Trimmer - MANSCAPED redesigned the traditional nose hair taming device by focusing on the highest performance and comfort; equipped with SkinSafe technology, a 9,000 RPM motor, and 360-degree rotary dual-blade system
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver Ball Deodorant
- Crop Reviver Ball Toner
- The Shed & MANSCAPED Boxers
To learn more and to purchase any of these new products or packages, visit MANSCAPED.com, a one-stop-shop destination website designed for customers in the United Kingdom, European Union, Norway, Switzerland, Australia, New Zealand, Canada and more regions to come this year.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist, trusted by over 2 million men worldwide. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target, Best Buy, and Macy’s stores throughout the U.S. and Hairhouse locations in Australia. For more information, visit the website or follow on Facebook, Instagram, Twitter, TikTok, YouTube, and Triller.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005277/en/
Contact information
MANSCAPED, Inc.
Allison Frazier, Director of Public Relations
allison@manscaped.com
925-216-2791
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom